Bridge Medicines Signs Agreement with The Rockefeller University for Further Preclinical Development of Breslow Lab Assets

NEW YORK, NEW YORK – September 21, 2020

Bridge Medicines and The Rockefeller University today announced an exclusive license agreement to further develop a series of small molecule inhibitors of activated Factor XII (FXIIa) discovered in the laboratory of Jan L. Breslow, M.D.